Navigation Links
SCI patients treated with own olfactory ensheathing cells realize neurologic improvement
Date:6/28/2013

Putnam Valley, NY. (June 28 2013) A team of researchers in Poland who treated three of six paraplegics with spinal cord injury using transplanted olfactory ensheathing cells found that the three treated patients showed neurological improvement and no adverse effects while the three control patients who did not receive transplants saw no improvement.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0799tabakow.

"Most accepted treatments for spinal cord injury focus on techniques of early neuro-protection aimed at maximum prevention of secondary spinal cord injury and methods to stimulate plasticity in the central nervous system," said study corresponding author Dr. Pawel Tabakow of the Department of Neurosurgery, Wroclaw Medical University in Wroclaw, Poland. "These measures have helped patients with incomplete spinal injury, but results in patients with complete spinal injury remained limited."

According to the researchers, among the various kinds of neurotrophic cells being tested for transplantation to treat spinal cord injury, OECs deserve "special attention" because they are unique in their natural ability to stimulate regrowth of lesioned axons and "evoke long-distance axon regeneration and subsequent recovery of locomotion in paralyzed limbs."

The researchers noted specifically several laboratory studies using animals modeled with spinal cord injury where OECs derived from the olfactory mucosa have been found to stimulate the regrowth of neural nerves when transplanted into laboratory rats with paralyzed limbs. In those studies they found evidence of restored breathing, locomotion and climbing behavior in the animals.

In a phase one of this non-randomized controlled study, the team of researchers treated the three patients with transplanted self-donated (autologous) OECs and fibroblasts isolated from olfactory mucosa combined with "intense" neuro-rehabilitation. They found the treatment "safe and feasible" one year after transplantation. There was no evidence of neurological deterioration, neuropathic pain, neuroinfection or tumor growth, wrote the researchers.

"Neurophysiological examinations showed improvement in spinal cord transmission and activity of lower extremity muscles in the surgically treated patients, but not in patients receiving only neuro-rehabilitation," they said.

"We consider that the transplantation of OECs was the main factor contributing to the neurologic improvements in the three transplanted patients," said Dr. Tabakow. "Among the possible mechanisms for improvement is that the transplanted OECs may have mediated some restitution along white matter tracts in these patients."

The researchers added that the modest improvements in neurological function occurred against a "background of intense neuro-rehabilitation, which is probably needed for the improvements, although the experience of the control patients indicated that this in itself is not sufficient."


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related medicine news :

1. Acid reflux surgery could help prevent rejection in lung transplant patients
2. Surgeons report melanoma recurs after 10 years in more than 6 percent of patients
3. Lowering costs for higher-cost medicare patients through better outpatient care may be limited
4. Nurse practitioners can boost quality of care for older patients with chronic conditions
5. PET-CT improves care of limited-stage small-cell lung cancer patients
6. hCG Treatments / Diet Doc hCG Diets and Weight Loss Plans Offers New hCG Diet Plans to Help Patients Avoid Unsightly Stretch Marks With Supervised Fast Weight Loss
7. New Dental Plan Makes Dental Care More Affordable for Laura Torrado’s and Dr. Shawn Sadris' Patients
8. RSNA: Exercise Benefits Patients with Type 2 Diabetes
9. Exercise benefits patients with type 2 diabetes
10. Health Insurance for Patients with Mental Illness and Substance Use
11. Jackson, MS Periodontist, Dr. Roger Parkes Brings Gum Disease Patients the FDA-cleared Laser Gum Disease Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... contaminated soil, dredged material, and hazardous and non-hazardous materials announced today the acquisition ... This acquisition will add four additional processing facilities and a vast array ...
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association ... The annual awards, now in their 12th year, are among the most prestigious in ... In 2016, the awards were retooled to recognize achievements in both large budget (over ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher ... Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat with world ... and spiritual journey during the Summer Solstice will also be her final international ...
(Date:3/24/2017)... ... ... The law firm of Enea, Scanlan & Sirignano, LLP, with ... C. Enea has joined the firm as an associate attorney. Ms. Enea, who previously ... law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha A. Lyons, ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding ... God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with ... Walk with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical ... diseases in children, today reported financial results for ... 31, 2016 and provided an update on its ... make progress during the fourth quarter of 2016 ... primate safety study, and with our lead development ...
(Date:3/24/2017)... , March 24, 2017 Abdominal Aortic Aneurysm Repair Devices ... by 2022, Globally, registering a CAGR of 5.1% from 2016 to 2022. The endovascular ... to dominate the market during the study period. Continue ... ... ...
(Date:3/24/2017)... , Mar. 24, 2017 Research ... Management in the U.S.: Consumer Strategies" report to their ... ... how adults approach and treat their physical pain, emphasizing consumer ... distinct groups: pain sufferers and adults who have selected illnesses/conditions ...
Breaking Medicine Technology: